Institute of Human Biology: Pioneering the Future of Drug Development

The Institute of Human Biology (IHB) at Roche is at the forefront of transforming healthcare through innovative human model systems. Traditional drug development is lengthy and costly, with many candidates failing due to reliance on models that don‘t adequately refl ect human biology. IHB is revolutionizing this process with advanced organoid research—miniature, simplifi ed versions of human tissues and organs that improve the accuracy of predicting clinical success.

Launched in May 2023, IHB is devoted to organoid research and represents an example of Roche’s commitment to groundbreaking innovations. IHB unites expertise in exploratory biology, biomedicine, translational bioengineering, and computation under one roof. Cutting-edge technology, including high-throughput organoid analysis and microfl uidics, position IHB at the global forefront of human biology.

Situated in Basel, Switzerland, IHB combines academic-style research with industry know-how to tackle real-life drug development challenges. Collaborations with leading academic institutions foster the next generation of translational biomedical talent.

There is still a way to go before organoids reach widespread application. Roche’s IHB will play a key role in advancing this technology — contributing to the longterm vision to revolutionise the industry and bring transformative medicines topatients in need.